Aprea Secures $30M Financing, APR-1051 Shows 59.5% Tumor Reduction
Aprea Therapeutics secured approximately $30 million in an oversubscribed private placement featuring pre-funded warrants for roughly 37.2 million shares at $0.808 each and detachable warrants exercisable at $0.683, extending its cash runway into Q1 2028. Its ACESOT-1051 Phase 1 trial of APR-1051 reported a confirmed partial response at a 220mg daily dose, demonstrating a 59.5% reduction in target lesion size across two assessments and CA-125 levels falling from 362 to 40.2 U/ml.
1. Oversubscribed $30M Private Placement
Aprea executed an oversubscribed private placement securing gross proceeds of approximately $30 million before fees and expenses, featuring pre-funded warrants for 37.2 million shares at $0.808 per warrant and detachable warrants exercisable at $0.683 per share.
2. Confirmed Partial Response in APR-1051 Trial
The ACESOT-1051 Phase 1 study reported a confirmed partial response in a PPP2R1A-mutated endometrial cancer patient treated at 220 mg once daily, achieving an initial 50% tumor reduction followed by an additional 9.5% decrease and a drop in CA-125 levels from 362 to 40.2 U/ml.
3. Use of Proceeds and Development Timeline
Aprea intends to apply net proceeds toward general corporate purposes and R&D, with the financing extending cash runway into Q1 2028; the company plans to complete dose escalation by Q2 2027 and enroll at least 50 patients with uterine serous carcinoma and platinum-resistant ovarian cancer.